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Introduction: We aimed to assess differences in breast cancer risk across benign breast disease diagnosed
at prevalent or incident screens.
Materials and methods: We conducted a retrospective cohort study with data from 629,087 women
participating in a long-standing population-based breast cancer screening program in Spain. Each benign
breast disease was classified as non-proliferative, proliferative without atypia, or proliferative with
atypia, and whether it was diagnosed in a prevalent or incident screen. We used partly conditional Cox
hazard regression to estimate the adjusted hazard ratios of the risk of breast cancer.
Results: Compared with womenwithout benign breast disease, the risk of breast cancer was significantly
higher (p-value ¼ 0.005) in women with benign breast disease diagnosed in an incident screen (aHR,
2.67; 95%CI: 2.24e3.19) than in those with benign breast disease diagnosed in a prevalent screen (aHR,
1.87; 95%CI: 1.57e2.24). The highest risk was found in women with a proliferative benign breast disease
with atypia (aHR, 4.35; 95%CI: 2.09e9.08, and 3.35; 95%CI: 1.51e7.40 for those diagnosed at incident and
prevalent screens, respectively), while the lowest was found in women with non-proliferative benign
breast disease (aHR, 2.39; 95%CI: 1.95e2.93, and 1.63; 95%CI: 1.32e2.02 for those diagnosed at incident
and prevalent screens, respectively).
Conclusion: Our study showed that the risk of breast cancer conferred by a benign breast disease differed
according to type of screen (prevalent or incident). To our knowledge, this is the first study to analyse the
impact of the screening type on benign breast disease prognosis.
© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Epidemiologia I Avaluacio. Passeig Marítim 25-29, Barcelona, 08003, Spain.
astells).
Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Benign breast disease is associated with an increased risk of
breast cancer both in the clinical setting [1,2] and in population-
based screening [3]. Quantification of the increased risk according
to the characteristics of each lesion is constantly under study.
Benign breast disease lesions are most commonly classified as non-
proliferative lesions, proliferative lesions without atypia, or prolif-
erative lesions with atypia [4e6]. The risk of subsequent breast
cancer is higher in proliferative lesions than in non-proliferative
lesions, while the risk is highest in proliferative lesions with aty-
pia [3,7].
Benign breast disease has been proposed as a key risk factor in
several breast cancer risk prediction models [8e11]. These models
are essential for the development of personalised screening stra-
tegies designed to improve the risk-benefit balance of breast cancer
screening [12,13]. Therefore, it is important to fully understand
differences in breast cancer risk in women diagnosed with benign
breast disease.
In population-based breast cancer screening in Spain, women
are invited to undergo a mammographic examination every 2 years
from the age of 50e69 years. Mammographic examinations can
therefore be classified as prevalent screens, ie, women’s first
participation in screening mammography, and incident screens, ie,
all subsequent screening participations. The results of prevalent
and incident screens differ in several screening outcomes, such as a
higher detection rate and a higher recall rate at prevalent screens
[14], resulting in higher sensitivity and lower specificity [15,16].
However, breast cancer diagnosed at prevalent screens has been
shown to be less aggressive and to have slower growth [17,18]. Even
so, no studies have evaluated the risk of breast cancer associated to
bening breast disease according to type of examination (incident or
prevalent). We hypothesised that benign breast disease diagnosed
in a prevalent screen confer a lower risk of subsequent breast
cancer than that diagnosed in incident screens, regardless of the
benign breast disease subtype.
Using data from a long-standing population-based screening
program in Spain, we aimed to assess differences in the risk of
breast cancer after diagnosis of benign breast disease according to
the screening type and histological subtype of benign breast
disease.
2. Materials and methods
2.1. Study design and participants
The Spanish Breast Cancer Screening Program follows the rec-
ommendations of the European Guidelines for Quality Assurance in
Breast Cancer Diagnosis [19]. At age 50 years, women are invited to
undergo 2-dimensional digital screening mammography. Two
projections (mediolateral-oblique and craniocaudal views) are
interpreted according to the Breast Imaging Reporting and Data
System (BI-RADS) [20] scale by trained breast radiologists. Women
with abnormal mammographic findings are recalled for further
assessments to confirm or rule out malignancy. Women without a
breast cancer diagnosis are invited back for routine screening at 2
years.
We analysed data from seven centres in the Spanish Screening
program, which routinely gathers information on benign breast
disease diagnoses. The study population included 632,299 women
who underwent at least one screening mammogram between 1994
and 2015 and who were followed up until December 2017. Due to
the longitudinal nature of the study, women with breast cancer
diagnosed in their first screen (n ¼ 3,212) were excluded from the
analyses as there was no time for follow-up, leaving left 629,087344women for the analysis.
2.2. Procedures
All women with screening mammograms scored BIRADS 0, 3, 4
or 5 were recalled for further assessments. If cancer could not be
ruled out with non-invasive procedures when women were
attending recall, core-needle or open biopsy was performed. All
biopsies were examined and classified by hospital pathologists in
each screening centre. All biopsies with a non-malignant classifi-
cation were classified as benign breast disease. Following the
criteria of Page et al. and Dupont et al. [4e6], we classified benign
breast diseases as: non-proliferative, proliferative without atypia,
and proliferative with atypia. Only women with asymptomatic
benign breast disease diagnosed at screening were included in the
study.
Both cancers detected at routine screening and interval cancers
(those diagnosed within 24 months after a negative screening
episode and before the next screening invitation) were included in
the study regardless of whether they were invasive or in situ. In-
terval cancers were identified by merging population-based cancer
registries and hospital-based cancer registries with data from
screening participants. Benign breast disease identified at the same
time as cancers were excluded from the benign breast disease
group.
2.3. Analysis
We used the chi-squared test to compare proportions of
different variables among those women without a benign breast
disease diagnosis, those with a diagnosis in a prevalent screen and
those with a diagnosis in an incident screen.
We calculated incident breast cancer rates using person-years at
risk for women with and without a diagnosis of benign breast
disease. Womenwithout benign breast disease contributed person-
years at risk from the date of the first screening mammogram until
breast cancer diagnosis (screen-detected or interval cancer), benign
breast disease diagnosis, or 2 years after the last mammographic
examination, whichever came first. Women with benign breast
disease contributed person-years at risk from the date of benign
breast disease diagnosis until breast cancer diagnosis or 2 years
after last screening examination, whichever occurred first.
We used a partly conditional Cox proportional hazards model to
estimate the adjusted hazard ratios (aHR) and the 95% confidence
intervals (95%CI) for the risk of breast cancer by screening type and
benign breast disease subtype. These models are an extension of
the Cox hazards model for repeated measures, which allowed us to
update the changes in benign breast disease status during the study
period. All analyses were adjusted for age and calendar year. We
adjusted for age because women with benign breast disease diag-
nosed in a prevalent screenwere expected to be younger than those
diagnosed in incident screens. Adjustment by calendar year was
included to capture possible differences in benign breast disease
diagnosis techniques and classification during the study period. An
interaction between screening type and benign breast disease
subtype was tested; the interactionwas found to be non-significant
and was consequently not included in the final models (p for
interaction ¼ 0.83). Robust standard errors were used to estimate
95% confidence intervals. The proportional hazards assumptionwas
assessed by plotting the log-minus-log of the survival function
against log time for each predictive variable. The proportional
hazards assumption was reasonable for all predictors.
We plotted the adjusted cumulative incidence curves by esti-
mating the age- and calendar-year adjusted risk of cancer devel-
opment of the average woman in each category with the partly
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values <0.05 were considered statistically significant. All analyses
were performed using the statistical software R version 3.5.0
(Development Core Team, 2014).3. Results
We analysed information from 629,087 womenwho underwent
2,327,384mammographic examinations between January 1994 and
December 2015. During the study period, 9431 cases of breast
cancer and 9184 cases of benign breast disease were diagnosed. We
found no differences in the distribution of benign breast disease
subtypes across incident and prevalent screens (p ¼ 0.48) (Table 1).
The proportion of breast cancer cases was significantly lower in
women without benign breast disease than in those with benign
breast disease (1.5% vs 2.7%, p < 0.001). Among women with a
diagnosis of benign breast disease, the proportion of breast cancer
cases was higher inwomen diagnosed in an incident screen than in
those diagnosed in a prevalent screen (3.0% vs 2.4%, p ¼ 0.07).
Women with benign breast disease had a higher risk of breast
cancer than those without benign breast disease, regardless of the
subtype of benign breast disease. The highest risk was found in
women with proliferative benign breast disease with atypia (aHR,
3.82; 95%CI: 2.23e6.56), followed by those with proliferative
benign breast disease without atypia (aHR, 3.19; 95%CI: 2.46e4.13)
and those with non-proliferative benign breast disease (aHR, 1.95;
95%CI: 1.68e2.27) (Fig. 1). In addition, among women with benign
breast disease, risk was higher in those diagnosed in an incident
screen than in those diagnosed in a prevalent screen (aHR, 2.67;
95%CI: 2.24e3.19, and aHR, 1.87; 95%CI: 1.57e2.24, respectively).
The hazard ratios associated within each combination of
screening type and benign breast disease subtype are shown in
Fig. 2. Across benign breast disease subtypes, those diagnosed in an
incident screen conferred a higher risk than those diagnosed in
prevalent screens, although not statistically significant for al sub-
types. Compared with womenwithout a benign breast disease, the
highest risk was found in those women with a proliferative benign
breast disease with atypia (aHR, 4.35; 95%CI: 2.09e9.08, and 3.35;
95%CI: 1.51e7.40 for those diagnosed at incident and prevalent
screens, respectively, p-value for comparison; p ¼ 0.634), followed
by women with proliferative benign breast disease without atypia
(aHR, 3.83; 95%CI: 2.63e5.58, and 2.78; 95%CI: 1.95e3.96 for those
diagnosed at incident and prevalent screens, respectively; p-value
for comparison p ¼ 0.223). The lowest was found in women withTable 1
Characteristics of the study population.
No benign breast disease N ¼ 619,864









Type of benign breast disease
No benign breast disease 619,864 (100%)
Non-proliferative 0 (0.0%)
Proliferative without atypia 0 (0.0%)




345non-proliferative benign breast disease (aHR, 2.39; 95%CI:
1.95e2.93, and 1.63; 95%CI: 1.32e2.02 for those diagnosed at
incident and prevalent screens, respectively, p-value for compari-
son; p ¼ 0.011).
We examined the adjusted cumulative incident curves of breast
cancer across the different classifications of benign breast disease
and screening types. The probability of breast cancer diverged over
time. The average 10-year breast cancer probability of women
without a benign breast disease diagnosis was 1.9%. Among women
with benign breast disease, the probability was higher in women
diagnosed in an incident screen than in those diagnosed in a
prevalent screen (average 10-year probability of breast cancer 4.9%
vs 3.5%). Among benign breast disease subtypes, the highest
probability of cancer was found in women with a proliferative
benign breast disease with atypia followed by those with prolifer-
ative benign breast disease without atypia and those with a non-
proliferative benign breast disease (average 10-year breast cancer
probability 6.9%, 5.8% and 3.6%, respectively) (Fig. 3). The highest
probability was found in women with proliferative benign breast
disease diagnosed in an incident screen, with an average 10-year
probability of breast cancer of 7.8% (Fig. 4).4. Discussion
In this study of more than 600,000 women with follow-up for
more than 20 years, we found that a diagnosis of benign breast
disease in an incident screen conferred a higher risk of subsequent
breast cancer than diagnosis in a prevalent screen, regardless of the
histological subtype. These findings highlight the importance of
considering the screening type when benign breast disease was
diagnosed in risk of breast cancer estimation. To our knowledge,
this is the first study to include screening type in the assessment of
the impact of benign breast disease on the risk of subsequent breast
cancer.
Over the past decades, multiple studies have assessed the
relationship between benign breast disease and the risk of breast
cancer [2e6]. Particular efforts have been made to assess the as-
sociation of this risk with the various benign breast disease sub-
types [4e6]. As seen in previous reports, our study showed that
women with benign breast disease had an increased risk of breast
cancer [2]. Consistently, we found that the risk of breast cancer was
highest among women with a proliferative benign breast disease
with atypia, while proliferative benign breast disease without
atypia conferred a higher risk than non-proliferative benign breastBenign breast disease diagnosed
in a prevalent screen N ¼ 5,049
Benign breast disease diagnosed in an
incident screen N ¼ 4,174
3,420 (67.7%) 2,687 (64.4%)
758 (15.0%) 936 (22.4%)
637 (12.6%) 499 (12.0%)
234 (4.6%) 52 (1.2%)
2,111 (41.8%) 2,856 (68.4%)
1,220 (24.2%) 1,038 (24.9%)
1,718 (34%) 280 (6.7%)
0 (0.0%) 0 (0.0%)
3,948 (78.2%) 3,282 (78.6%)
877 (17.4%) 728 (17.4%)
224 (4.4%) 164 (3.9%)
4,928 (97.6%) 4,048 (97%)
121 (2.4%) 126 (3.0%)
Fig. 1. Adjusted hazard ratios (aHR) of breast cancer incidence in women with benign breast disease compared with women with negative screening tests.
Fig. 2. Adjusted hazard ratios (aHR) of breast cancer incidence in women with benign breast disease compared with women with negative screening tests testing the combined
effect of type of benign breast disease, and round at benign breast disease diagnosis.
Fig. 3. Adjusted survival curves for breast cancer incidence based on Cox proportional hazards model for women with benign breast disease vs women with negative screening
tests. Fig. 3 a. Solid line represents negative screening test group; dashed line represents benign breast disease diagnosed at prevalent round, dotted line benign breast disease
diagnosed in incident round. Fig. 3 b. Solid line represents negative screening test group; dashed line represents nonproliferative benign breast disease, dashdotted line represent
proliferative benign breast disease without atypia, dotted line represents proliferative benign breast disease with atypia.
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types led to non-significant differences in some subgroup com-
parisons, we found that the difference in risk across benign breast
disease subtypes remained proportional within prevalent and
incident screens and was systematically higher in those BBD
diagnosed in incident screens. This finding is particularly relevant
since 55% of benign breast diseases are diagnosed in prevalent
screens. Screening type therefore provides key information for risk
prediction in benign breast disease. Unless this information is346included, the risk attributed to benign breast disease diagnosed in
prevalent screens could be overestimated, and that for incident
screens could be underestimated.
Previous studies performed in the last decade have assessed
differences in breast cancer screening outcomes, such as cancer
detection rates and false positive rates, by screening type [14e16].
Moreover, previous authors found differences in breast cancer
characteristics depending on whether the cancers were diagnosed
in a prevalent or incident screen [17,18], suggesting that latent
Fig. 4. Adjusted survival curves for breast cancer incidence based on Cox proportional
hazards model for women with benign breast disease vs women with negative
screening tests.
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pattern. The lower risk of breast cancer observed in women with
benign breast disease diagnosed in prevalent screens might be
partially explained by a slower growth pattern in prevalent benign
breast disease. Age may play an important role in this effect, since
women with benign breast disease diagnosed in incident screens
are, on average, older than those diagnosed in a prevalent screen.
However, to control for this potential confounding effect, we
adjusted all analyses by age and calendar year.
The results of this study may have implications for clinical de-
cisions on the follow-up of women with a diagnosis of benign
breast disease, in which distinct follow-up strategies may be rec-
ommended depending on the benign breast disease subtype and
screening type at diagnosis. The findings may also have implica-
tions for individualised risk prediction. The Breast Cancer Surveil-
lance Consortium model [21] is being used in a large international
randomised clinical trial to define the individual risk of the popu-
lation targeted for breast cancer screening with a view to offering
them personalised screening strategies [22]. Our findings reveal
that screening type explained part of the risk associated with
benign breast disease. Taking this variability into account could
help to improve the discriminatory power of breast cancer risk
prediction models, which is commonly moderate [11,23]. In addi-
tion, we found that womenwith proliferative benign breast disease
diagnosed in an incident screen had a 4-fold higher risk of devel-
oping breast cancer than those without. This information, after
further analysis with adjustment for other risk factors such as
breast density [24], family history [25], or a risk score using infor-
mation from single nucleoid polymorphisms [26], may be key to
defining risk groups that could benefit from tailored screening
strategies.
This study has some limitations. First, the number of cancers
detected after proliferative benign breast disease with atypia was
small because this subtype is uncommon, which limited our ca-
pacity to perform some subgroup analyses. Second, there is a
possible bias produced by temporary changes both in the benign
breast disease classification and in biopsy techniques (because fine-
needle aspiration cytology has become practically obsolete). This
bias is partially controlled as we adjusted our analysis by calendar
year. Third, to be able to classify benign breast disease, we restricted
our study to those benign breast diseases with available informa-
tion on their histological subtype. Last, it was not possible to adjust347the statistical analysis on other breast cancer risk factors such as
breast density or familial history of breast cancer.
A strength of this study is that we analysed a large cohort of
more than 600,000 women screened in a well-established popu-
lation-based screening program with a 20-year follow-up. This is
one of the largest cohorts analysing histopathologically confirmed
benign breast disease, with nearly 10,000 diagnoses during follow-
up.
In summary, our study shows that, regardless of the type of
benign breast disease, women with benign breast disease diag-
nosed in an incident screen have a significantly higher subsequent
risk of breast cancer than those with a benign breast disease
diagnosed in a prevalent screen. To our knowledge, this is the first
study to analyse this topic. It is important to consider this risk when
developing risk-based personalised screening strategies.Funding
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